logo


PicksThatMove.Com Announces Investment Opinion: Small Cap Biopharmaceuticals and Biotechnology 101 From PicksThatMove
Tuesday, September 15, 2009 5:51 PM


(Source: Business Wire)trackingPicksThatMove.com opines promising trading opportunities with likely potential for gain. The companies we follow have favorable revenue models for business development at upward cycles. Please visit us at PicksThatMove.com to view more of our profiled stocks.

Morning movers in biopharmaceutical sector include: GenovaBiotherapeutics Inc. (OTCBB:GVBP) up 84% closing at $0.80, Tenet Healthcare Corp (NYSE:THC) down 0.17% trading at $5.75, Discovery Laboratories Inc. (NASDAQ:DSCO) down 5% trading at $1.01, ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA) down 7% trading at $2.54 and KERX Biopharmaceuticals Inc. (NASDAQ:KERX) up 1.30% trading at $1.55.

Our intention is bringing knowledge to beginners who wish to learn more about stock trading.

Small-cap, penny stock biopharmaceutical companies have attributed to massive payoffs when stock prices surge on news.

There are identifiable variables driving profit in the biopharmaceutical sector, for example: news of mergers & acquisitions; anticipated research and positive clinical data results; pending applications granted FDA clearance and approval; and government support.

The most recent Ernst & Young annual biotechnology report shows that mergers & acquisitions were worth $28.5 billion over the last year in the US alone. The less obvious benefit of these massive biotech deals forecast a strengthening of credit markets as bankers are willing to endorse them.

Positive clinical data is another major influence on stock appreciation, auguring high end double digit percentage gains almost immediately for penny stocks; while FDA clearance and approval exponentially increases the value of a stock as a gatekeeper to market entry internationally.

Government support and healthcare initiatives are also major drivers in the sector. At the National Academy of Sciences President Barack Obama announced the government should spend more than 3% of its GDP scientific R&D. The US has earmarked a $3.5 trillion budget for fiscal 2010 requiring the development of generic, cost effective biotech drugs that will create competition in the market as well as proposals to inhibit Big Drugs, and brand name companies from using anti-competitive agreements to keep inexpensive small cap comers off the market.

Sign up for our FREE alerts at Picksthatmove.com

About Picksthatmove.com

Picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. Picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at editorial@picksthatmove.com.

Picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. Picksthatmove.com is not a registered investment advisor or broker-dealer. Picksthatmove.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

Nick Hunter, RIA, of Picksthatmove.com is a member of the National Association of Securities Dealers, CRD number 2022366

A service of YellowBrix, Inc.



(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

  
Related Press Releases
Advertisement
Popular Articles
Advertisement
Partner Center
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia